ProCE Banner Activity

MM24: Updated Data and Guidelines on COVID-19 Treatments

Multimedia
In this presentation, Professor Sharon Lewin discusses the FDA approval of remdesivir and the data from the ACTT-1 and WHO SOLIDARITY trials.

Released: October 30, 2020

Expiration: October 29, 2021

No longer available for credit.

Share

Faculty

Sharon R. Lewin

Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director
Doherty Institute
Melbourne Laureate Professor and Head
Department of Infectious Diseases
The University of Melbourne
Consultant Physician
Victorian Infectious Diseases Service
Royal Melbourne Hospital
Consultant Physician and Adjunct Professor Department of Infectious Diseases
Alfred Hospital and Monash University
Melbourne, Australia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director
Doherty Institute
Melbourne Laureate Professor and Head
Department of Infectious Diseases
The University of Melbourne
Consultant Physician
Victorian Infectious Diseases Service
Royal Melbourne Hospital
Consultant Physician and Adjunct Professor Department of Infectious Diseases
Alfred Hospital and Monash University
Melbourne, Australia

Sharon Lewin, AO, FRACP, PhD, FAAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.